Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an
HepG2
MCF-7
MDM2
MDM2 inhibitor
PET
SP-141
fluorine-18
imaging
radiotracer
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
13 Apr 2021
13 Apr 2021
Historique:
received:
11
03
2021
revised:
05
04
2021
accepted:
09
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
Murine double minute 2 (MDM2), a negative regulator of the p53 tumor suppressor protein, is overexpressed in several human cancers. Herein we investigate the feasibility of developing
Identifiants
pubmed: 33924734
pii: ph14040358
doi: 10.3390/ph14040358
pmc: PMC8070256
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : R21 CA241823
Pays : United States
Organisme : NIH HHS
ID : CA241823
Pays : United States
Références
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):E3445-54
pubmed: 23946421
Cancer Res. 1993 Jun 15;53(12):2736-9
pubmed: 8504413
J Nucl Med. 2010 Nov;51(11):1805-12
pubmed: 20956468
Sci Rep. 2017 May 11;7(1):1763
pubmed: 28496125
Mol Cancer Res. 2017 Nov;15(11):1598-1607
pubmed: 28784612
J Med Chem. 2013 Jul 25;56(14):5979-83
pubmed: 23808545
Invest New Drugs. 2020 Jun;38(3):831-843
pubmed: 31359240
Int J Clin Exp Pathol. 2013 Jun 15;6(7):1306-16
pubmed: 23826411
Nucleic Acids Res. 2017 Feb 28;45(4):1793-1804
pubmed: 27903893
ACS Med Chem Lett. 2018 May 01;9(7):606-611
pubmed: 30034587
PeerJ. 2014 Feb 27;2:e270
pubmed: 24688849
Eur J Med Chem. 2016 Aug 25;119:218-30
pubmed: 27163884
Cancer Cell. 2006 Dec;10(6):501-14
pubmed: 17157790
Biomed Chromatogr. 2015 May;29(5):654-63
pubmed: 25294254
J Med Chem. 2015 Feb 12;58(3):1038-52
pubmed: 25396320
Clin Cancer Res. 2016 Feb 15;22(4):868-76
pubmed: 26459177
Biomed Res Int. 2013;2013:759057
pubmed: 23710458
Nat Commun. 2014 Oct 01;5:5086
pubmed: 25271708
Cancer Res. 1993 May 15;53(10 Suppl):2231-4
pubmed: 8387391
Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11
pubmed: 1933891
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
Genes Dis. 2019 Jun 19;6(4):419-430
pubmed: 31832522
Cell. 2017 Sep 7;170(6):1062-1078
pubmed: 28886379
Mol Imaging. 2014;13:
pubmed: 25022573
Gastroenterology. 2014 Oct;147(4):893-902.e2
pubmed: 25016295
Haematologica. 2016 May;101(5):e185-8
pubmed: 26869629
Oncogene. 1997 Aug 28;15(9):1001-10
pubmed: 9285554
Oncogene. 2017 Jul 13;36(28):3943-3956
pubmed: 28288132
Breast Cancer Res Treat. 1996;37(2):179-88
pubmed: 8750585
Mod Pathol. 2006 Jan;19(1):69-74
pubmed: 16258514
Pharmacol Ther. 2017 Oct;178:92-108
pubmed: 28351719
Cell. 1997 Oct 31;91(3):325-34
pubmed: 9363941
Nature. 1997 May 15;387(6630):296-9
pubmed: 9153395
Curr Cancer Drug Targets. 2005 Feb;5(1):27-41
pubmed: 15720187
Cells. 2020 Jul 01;9(7):
pubmed: 32630235
Drug Des. 2017 Mar;6(1):
pubmed: 29354330